Publications by authors named "Matthew French-Kim"
For patients with high-risk or relapsed/refractory acute myeloid leukemia (AML), allogeneic stem cell transplantation (allo-HSCT) and the graft-versus-leukemia effect mediated by donor T cells, offer the best chance of long-term remission. However, the concurrent transfer of alloreactive T cells can lead to graft-versus-host disease that is associated with transplant-related morbidity and mortality. Furthermore, ∼60% of patients will ultimately relapse after allo-HSCT, thus, underscoring the need for novel therapeutic strategies that are safe and effective.
View Article and Find Full Text PDFArticle Synopsis
- This study tested a new cancer treatment using multi-antigen-targeted T cells (multiTAA-T) for patients with advanced breast cancer, focusing on safety and effectiveness.* -
- Ten patients with heavily treated breast cancer were given two infusions of these T cells, and while most experienced disease progression, one patient showed a significant stabilization of their condition for five months with no major side effects observed.* -
- The treatment led to specific T-cell expansion and the activation of T cells against other cancer-related antigens, hinting at a broader immune response and potential for improving future therapies.*
Multiple myeloma (MM) is an almost always incurable malignancy of plasma cells. Despite the advent of new therapies, most patients eventually relapse or become treatment-refractory. Consequently, therapies with nonoverlapping mechanisms of action that are nontoxic and provide long-term benefit to patients with MM are greatly needed.
View Article and Find Full Text PDFArticle Synopsis
- The objective of the study was to compare the cost-effectiveness of pharmacogenetic-guided dosing of warfarin versus the standard dosing method using a Markov model.
- The analysis found that the pharmacogenetic strategy led to a slight increase in quality-adjusted life years (QALYs) but resulted in higher costs, resulting in an incremental cost-utility ratio (ICUR) indicating it was not cost-effective.
- The conclusion drawn suggests that pharmacogenetic-guided dosing for warfarin does not offer a superior cost-utility benefit compared to standard dosing practices.